SESSION 2 | 15:20 – 16:37
Innovation in Treatment Modalities (II)
Moderators: Frank Holz/ Ramin Tadayoni
15:20
Cedric Francois: Apellis — Role of pegcetacoplan, a C3 anti-complement inhibitor, for the therapy of GA
15:28
Erin Henry: IVERIC Bio — Innovation in treatment for Geographic Atrophy: Avacincaptad pegol anti-C5 complement inhibition
15:36
Riad Sherif: Oculis — Rethinking Ophthalmology
15:44
David Tanzer: Ocuterra Therapeutics — Innovation in treating diabetic retinopathy: A novel, topically delivered selective integrin inhibitor
15:52
Justin Creel: Novartis — Next generation drug delivery to the back of the eye
16:00
Ulrike Graefe-Mody: Boehringer Ingelheim — How innovation will drive a new era of vision preservation and protection
16:08
Antony Mattessich: Ocular Therapeutix — Transformative investigational tyrosine kinase inhibitor therapy for retinal vascular diseases
16:16 – 16:37: Panel Discussion
Andrew Dick: Cirrus
Mohamed Genead: Aviceda Therapeutics Inc.
Ulrich Granzer: Granzer Regulatory Consulting
Jane Moseley: EMA
Charles Wykoff: Houston Methodist Hospital & Blanton Eye Institute
